CANADA: HIV Postexposure Prophylaxis Use Among Ontario Female Adolescent Sexual Assault Victims: A Prospective Analysis CDC Daily UpdateImportant note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.

Click here to return to CDC Daily Update main menu





DonateNow




CANADA: HIV Postexposure Prophylaxis Use Among Ontario Female Adolescent Sexual Assault Victims: A Prospective Analysis

Sexually Transmitted Diseases Vol. 35; No. 12: P. 973-978 (12..08) - Monday, December 22, 2008
Janice Du Mont, EdD; Terri L. Myhr, MSc; Heather Husson, BA; Sheila Macdonald, MN; Anita Rachlis, MD; Mona R. Loutfy, MD, MPH


The authors examined HIV post-exposure prophylaxis (PEP) - its provision, uptake, adherence, and other related factors - among female sexual assault survivors from September 2003 to January 2005.

Sexual assault patients of all ages were universally offered PEP through the HIV PEP Project. The investigators collected baseline and follow-up data from consecutive clients seen at 18 hospital-based sexual assault treatment centers in Ontario.

Among 386 patients, 94.5 percent were single, 68 percent lived with their family, and 67.4 percent were attending school. Just 42.7 percent accepted PEP and 33.6 percent completed the 28-day course of drugs. The factors associated with uptake were provider encouragement, being a student, and being moderately to highly anxious. Completion of the full PEP course was associated with being white and knowing the assailant for less than 24 hours.

"Our findings highlight the importance of the health care provider's role in counseling sexually assaulted female adolescents about HIV PEP use," concluded the authors. "The results also suggest that at-risk adolescents not enrolled in school and those from culturally diverse backgrounds may require additional supports."
081222
AD082391


Copyright © 2008 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.

.